https://www.selleckchem.com/pr....oducts/Paclitaxel(Ta
The discovery of immune checkpoints and their role in modulating immune response have revolutionised cancer treatment in recent years. The immune checkpoints, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1) and its ligand, programmed cell death-ligand 1 (PD-L1), have been extensively studied. Currently seven monoclonal antibodies targeting these immune checkpoints are approved for treatment of various cancers. Inhibiting immune checkpoints has shown some success in clinic, however,
Like
Comment
Share
